Cabaletta Bio, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cabaletta Bio, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($167.86M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($115.86M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($67.68M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($52.98M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($46.29M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($33.34M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($16.94M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($12.20M) | Mar 30, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($172.24M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($125.14M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($74.66M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($54.14M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($46.31M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($33.83M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($18.68M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($6.19M) | Mar 30, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.67M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $97.20M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $55.42M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $39.30M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $32.49M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $21.38M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $11.67M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $4.47M | Mar 30, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($131.08M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($88.22M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($53.55M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($46.38M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($34.11M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($26.77M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($16.05M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($4.66M) | Mar 30, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $2.21M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $687.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.45M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.17M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $635.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $693.0K | Mar 16, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.08M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $185.05M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $253.65M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $116.97M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $126.34M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $114.72M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $141.47M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $34.17M | Mar 30, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.03M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $32.71M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $17.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.45M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $8.38M | Mar 16, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.05M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $152.34M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $236.20M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $104.52M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $117.96M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $109.54M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $138.32M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | ($10.69M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | ($249.0K) | Mar 30, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($516.96M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($349.10M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($233.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($165.56M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($112.59M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($66.30M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($32.96M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($12.45M) | Mar 30, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.98M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $163.96M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $193.24M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $81.61M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $122.22M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $101.43M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $136.20M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $33.02M | Mar 30, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 100.48M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 50.74M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 47.82M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 29.45M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | 28.93M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 24.06M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 24.03M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | 3.85M | Mar 30, 2020 |